Prospective clinical trial registration

Journal of Investigative Dermatology

Volumn 124, Issue 5, 2005, Pages

  Williams, Hywel C ^a   Stern, Robert S ^b  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIPOTRIOL; CYCLIC AMP; GAMMA INTERFERON; MESSENGER RNA; VITAMIN D;

ANTIMICROBIAL ACTIVITY; CLINICAL STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG MECHANISM; GENETIC SUSCEPTIBILITY; HAIR FOLLICLE; HUMAN; INFLAMMATION; LENTIGO; NOTE; PEDIGREE ANALYSIS; PRIORITY JOURNAL; PROFESSIONAL STANDARD; PROSPECTIVE STUDY; PSORIASIS; PUBLICATION; REGULATORY MECHANISM; RISK FACTOR; SKIN PROTECTION; ULTRAVIOLET RADIATION;

EID: 18244382779     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1747.2005.23800.x     Document Type: Editorial

References (16)

1. Abbasi K: Compulsory registration of clinical trials. BMJ 329:637-638, 2004
2. Adetugbo K, Williams H: How well are randomized controlled trials reported in the dermatology literature? Arch Dermatol 136:381-385, 2000
3. Bigby M, Stern RS, Bigby JA: An evaluation of method reporting and use in clinical trials in dermatology. Arch Dermatol 121:1394-1399, 1985
4. Chalmers I: In the dark: Drug companies should be forced to publish all the results of clinical trials. New Sci 181:19, 2004
5. De Angelis C, Drazen JM, Frizelle FA, et al: International Committee of Medical Journal Editors. Clinical trial registration: A statement from the International Committee of Medical Journal Editors. Lancet 364:911-912, 2004
6. Diepgen TL: Early Treatment of the Atopic Child Study Group. Long-term treatment with cetirizine of infants with atopic dermatitis: A multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol 13:1378-286, 2002
7. Gordon KB, Papp KA, Hamilton TK, et al: Efalizumab for patients with moderate to severe plaque psoriasis: A randomized controlled trial. JAMA 290:3073-3080, 2003
8. Hoare C, Li Wan Po A, Williams H: Systematic review of treatments for atopic eczema. Health Technol Assess 4:1-191, 2000
9. Kempers S, Boguniewicz M, Carter E, et al: A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 51:515-525, 2004
10. Lebwohl M, Tyring SK, Hamilton TK, et al: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349:2004-2013, 2003
11. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B: Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: Review of studies in new drug applications. BMJ 326:1171-1173, 2003
12. Naldi L, Svensson A, Diepgen T, et al: European Dermato-Epidemiology Network. Randomized clinical trials for psoriasis 1977-2000: The EDEN survey. J Invest Dermatol 120:738-741, 2003
13. Rennie D: Thyroid storm. JAMA 277:1238-1243, 1997
14. Stern RS: A promising step forward in psoriasis therapy. JAMA 290:3133-3135, 2003
15. Williams H, Adetugbo K, Po AL, Naldi L, Diepgen T, Murrell D: The Cochrane Skin Group. Preparing, maintaining, and disseminating systematic reviews of clinical interventions in dermatology. Arch Dermatol 134:1620-1626, 1998
16. Williams HC: Evening primrose oil for atopic dermatitis. BMJ 327:1358-1359, 2003